-
51.发明申请公开(公告)号：US20130202594A1
公开(公告)日：2013-08-08
申请号：US13757672
申请日：2013-02-01
Applicant: Rupal S. BHATT , Ravindra Kumar , James W. Mier , Robert Pearsall , Matthew Sherman , Nicolas Solban
Inventor： Rupal S. BHATT , Ravindra Kumar , James W. Mier , Robert Pearsall , Matthew Sherman , Nicolas Solban
IPC: A61K38/45 , A61K31/404 , A61K31/44 , A61K31/436 , A61K31/4439 , A61K31/4709 , A61K31/517 , A61K39/395 , A61K31/506
CPC classification number: A61K38/45 , A61K31/404 , A61K31/436 , A61K31/44 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/517 , A61K45/06 , A61K47/68 , A61K47/6811 , C07K16/22 , C07K16/40 , C07K2319/30 , C12Y207/1103 , A61K2300/00
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
Abstract translation: 在某些方面，本公开内容涉及包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可以用于抑制体内肾细胞癌（RCC）的肿瘤生长的认识 。 在另外的方面，本公开涉及以下认识：包含ALK1的细胞外结构域的配体结合部分的多肽显着增加了护理受体酪氨酸激酶抑制剂标准物在体内抑制RCC肿瘤生长的能力。
-
公开(公告)号：US08455428B2
公开(公告)日：2013-06-04
申请号：US11982738
申请日：2007-11-02
Applicant: Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra
Inventor： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra
IPC: A61K38/00
CPC classification number: A61K39/39558 , A61K45/06 , C07K14/71 , C07K16/18 , C07K2317/52 , C07K2319/30
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
Abstract translation: 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 该公开内容还鉴定了ALK1的配体，并证明这些配体具有促血管生成活性，以及抑制受体 - 配体相互作用的抗体。
-
公开(公告)号：US08361957B2
公开(公告)日：2013-01-29
申请号：US13247748
申请日：2011-09-28
Applicant: Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
Inventor： Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
IPC: A61K38/00
CPC classification number: C12N9/12 , A61K38/179 , A61K38/1796 , C07K14/47 , C07K14/475 , C07K2319/30 , C12Q1/6897 , C12Y207/1103
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract translation: 在某些方面，本发明提供用于增加脊椎动物（包括啮齿动物和灵长类动物，特别是人）中红细胞和/或血红蛋白水平的组合物和方法。
-
54.发明授权Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators 有权使用GDF陷阱和促红细胞生成素受体激活剂的组合增加红细胞水平和治疗贫血的方法公开(公告)号：US08216997B2
公开(公告)日：2012-07-10
申请号：US12856420
申请日：2010-08-13
Applicant: Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
Inventor： Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
CPC classification number: C07K14/495 , A61K31/00 , A61K31/454 , A61K31/7068 , A61K38/1709 , A61K38/179 , A61K38/1796 , A61K38/1816 , A61K38/193 , A61K39/39533 , A61K45/06 , C07K14/475 , C07K14/505 , A61K2300/00
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract translation: 在某些方面，本发明提供用于增加脊椎动物（包括啮齿动物和灵长类动物，特别是人）中红细胞和/或血红蛋白水平的组合物和方法。
-
公开(公告)号：US08178488B2
公开(公告)日：2012-05-15
申请号：US12796332
申请日：2010-06-08
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
CPC classification number: C07K16/40 , A61K31/7088 , A61K38/00 , A61K38/1796 , A61P3/00 , A61P3/04 , A61P3/10 , A61P21/00 , C07K14/71 , C07K2319/30 , C12N5/0602
Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Abstract translation: 在某些方面，本发明提供通过施用ActRIIB信号传导途径的拮抗剂来增加产热脂肪细胞（例如，棕色脂肪细胞或其他表达UCP-1的脂肪细胞）的组合物和方法。 这些拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗肌生成抑制素抗体，抗GDF3抗体，抗淋巴结，抗激活素和抗GDF11抗体。 可以通过引起生热脂肪细胞的增加来治疗各种代谢和其它疾病。
-
Patent Agency Ranking
公开(公告)号：US20100316644A1
公开(公告)日：2010-12-16
申请号：US12796307
申请日：2010-06-08
Applicant: Jasbir Seehra , Ravindra Kumar
Inventor： Jasbir Seehra , Ravindra Kumar
IPC: A61K39/395 , C07H21/00 , C12N5/10 , C07K14/705 , C07K19/00 , A61K38/16 , A61P3/00 , A61P3/04 , A61P3/10 , A61P5/50 , A61P21/00
CPC classification number: C12N9/12 , A61K38/00 , C07K14/475 , C07K14/71 , C07K2319/30 , C12N2510/02 , C12Y207/1103
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Abstract translation: 在某些方面，本发明提供了用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪，棕色脂肪和/或神经元组织的生长并用于治疗代谢性疾病如糖尿病和肥胖的组合物和方法 ，以及与任何前述组织相关的疾病。
-
57.发明授权System and method for automatically upgrading/reverting configurations across a plurality of product release lines 有权用于在多个产品发布线上自动升级/恢复配置的系统和方法公开(公告)号：US07565519B1
公开(公告)日：2009-07-21
申请号：US11388106
申请日：2006-03-23
Applicant: Ravindra Kumar , Jonathan Mark Crowther
Inventor： Ravindra Kumar , Jonathan Mark Crowther
CPC classification number: G06F8/71
Abstract: A system and method for automatically upgrading/reverting of the software configurations in a storage system environment among a plurality of product release lines. A configuration upgrade/revert module of a storage system management module identifies a shortest path between an initial configuration and a desired end configuration using a transition table comprising of a plurality of transition functions. The upgrade/revert configuration module invokes the appropriate series of transition functions to modify the software configuration from the initial state to the desired end state.
Abstract translation: 一种用于在多个产品发布行之间在存储系统环境中自动升级/恢复软件配置的系统和方法。 存储系统管理模块的配置升级/恢复模块使用包括多个转换功能的转换表来标识初始配置和期望的端配置之间的最短路径。 升级/恢复配置模块调用适当的一系列过渡功能，将软件配置从初始状态修改为所需的结束状态。
-
58.发明申请Activin-actriia antagonists and uses for promoting bone growth in cancer patients 有权激活活性拮抗剂和用于促进癌症患者骨生长的用途公开(公告)号：US20090142333A1
公开(公告)日：2009-06-04
申请号：US12012525
申请日：2008-02-01
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
IPC: A61K39/395 , A61K38/17 , A61P35/04
CPC classification number: C07K16/3061 , A61K38/179 , A61K38/1796 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/71 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/02 , C07K2319/30
Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
Abstract translation: 在某些方面，本发明提供用于促进骨生长和增加骨密度以及用于治疗多发性骨髓瘤的组合物和方法。
-
公开(公告)号：US20090082270A1
公开(公告)日：2009-03-26
申请号：US12001494
申请日：2007-12-10
Applicant: Asya Grinberg , John Knopf , Ravindra Kumar , Jasbir Seehra
Inventor： Asya Grinberg , John Knopf , Ravindra Kumar , Jasbir Seehra
CPC classification number: C07K14/475 , A61K38/00 , A61K38/179
Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
Abstract translation: 本公开涉及用于治疗与肌生长抑制素，结节和GDF-11相关的多种疾病的Cerberus / Coco多肽或其变体。
-
60.发明申请Activin-actriia antagonists and uses for treating or preventing breast cancer 有权活化激活素拮抗剂和用于治疗或预防乳腺癌的用途公开(公告)号：US20090074768A1
公开(公告)日：2009-03-19
申请号：US12012510
申请日：2008-02-01
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
IPC: A61K39/395 , A61K38/00 , G01N33/566 , C12Q1/02 , A61P31/00
CPC classification number: C07K14/71 , A61K38/179 , A61K38/1796 , A61K45/06 , C07K14/705 , C07K2319/30 , C07K2319/32 , C12N9/12 , C12Y207/1103 , G01N33/5011 , G01N33/573 , G01N33/57415 , G01N2333/91205
Abstract: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
Abstract translation: 在某些方面，本发明提供用于治疗或预防人类乳腺癌的组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
90
records
(took 0.064 seconds)
